While research on CD32 and HIV is still in its early stages, the findings to date suggest that targeting CD32 may be a promising approach for the treatment of HIV infection. Further studies are needed to fully understand the role of CD32 in HIV pathogenesis and to translate these findings into clinical applications.
One specific area of interest is the role of CD32 in HIV latency. HIV latency is characterized by a state of viral dormancy, where the virus remains transcriptionally inactive despite being integrated into the host genome. CD32 has been identified as a marker for latently infected CD4+ T cells, which are a major reservoir for HIV.
